A role for glutamate in the treatment of anxiety and depression: Focus on group I metabotropic glutamate (mGlu) receptors

Drugs of the Future

Volumn 27, Issue 8, 2002, Pages 753-763

  Pilc, Andrzej ^a,b   Klodzinska, Aleksandra ^a   Nowak, Gabriel ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLOROKYNURENIC ACID; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CYCLOLEUCINE; CYCLOSERINE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EGLUMETAD; ELIPRODIL; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE RECEPTOR AGONIST; GLYCINE RECEPTOR ANTAGONIST; KAINIC ACID RECEPTOR ANTAGONIST; LY 392098; MDL 100458; MDL 102288; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MRZ 2 570; MRZ 2 571; MRZ 2 576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; HUMAN; MAZE TEST; NONHUMAN; OPEN FIELD TEST; REVIEW; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

EID: 0036707244     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.08.687386     Document Type: Review

References (137)

1. Vos, T., Mathers, C.D. The burden of mental disorders: A comparison of methods between the Australian burden of disease studies and the Global Burden of Disease study. Bull World Health Organ 2000, 78: 427-38.
2. Healy, D. Antidepressant therapy at the dawn of the third millennium. Br J Psychiatry 1998, 17: 392.
3. Murray, C.J., Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349: 1436-42.
4. Glass, R.M. Treating depression as a recurrent or chronic disease. JAMA 1999, 281: 83-4.
5. Brody, D.S., Hahn, S.R., Spitzer, R.L. et al. Identifying patients with depression in the primary care setting: A more efficient method. Arch Intern Med 1998, 158: 2469-75.
6. Barrett, J.E., Barrett, J.A., Oxman, T.E., Gerber, P.D. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988, 45: 1100-6.
7. Andrews, G., Sanderson, K., Slade, T., Issakidis, C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Organ 2000, 78: 446-54.
8. Zimmerman, M., Mcdermut, W., Mattia, J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiat 2000, 157: 1337-40.
9. Mcgeer, P.L., Mcgeer, E.G. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995, 21: 195-218.
10. Monaghan, D.T., Bridges, R.J., Cotman, C.W. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989, 29: 365-402.
11. Conn, P.J., Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37: 205-37.
12. Danysz, W., Parsons, C.G. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev 1998, 50: 597-664.
13. Pin, J.P., Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34: 1-26.
14. Wroblewski, J.T., Danysz, W. Modulation of glutamate receptors: Molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 1989, 29: 441-74.
15. Wiley, J.L., Cristello, A.F., Balster, R.L. Effects of site-selective NMDA receptor antagonists in an elevated plus- maze model of anxiety in mice. Eur J Pharmacol 1995, 294: 101-7.
16. Chojnacka-Wojcik, E., Klodzinska, A., Pilc, A. Glutamate receptor ligands as anxiolytics. Curr Opin Invest Drugs 2001, 2: 1112-9.
17. Skolnick, P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375: 31-40.
18. Skolnick, P., Legutko, B., Li, X., Bymaster, F.P. Current perspectives on the development of non-biogenic amine-based anti-depressants. Pharmacol Res 2001, 43: 411-22.
19. Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29: 23-6.
20. Danysz, W., Parsons, C.G., Bresnik, I., Quack, G. Glutamate in CNS Disorders. Drug News Perspect 1996, 8: 261-77.
21. Mavissakalian, M., Perel, J. Imipramine in the treatment of agoraphobia: Dose-response relationships. Am J Psychiat 1985, 142: 1032-6.
22. Corbett, R., Dunn, R.W. Effects of HA 966 on conflict, social interactions and plus maze behaviors. Drug Dev Res 1991, 24: 201-5.
23. Corbett, R., Dunn, R.W. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology 1993, 32: 461-6.
24. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989, 169: 1-10.
25. Karczkubicha, M., Jessa, M., Nazar, M. et al. Anxiolytic activity of glycine-B antagonists and partial agonists - No relation to intrinsic activity in the patch clamp. Neuropharmacology 1997, 36: 1355-67.
26. Plaznik, A., Palejko, W., Nazar, M., Jessa, M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994, 4: 503-12.
27. Davis, M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 1992, 13: 35-41.
28. Kehne, J.H., McCloskey, T.C., Baron, B.M. et al. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur J Pharmacol 1991, 193: 283-92.
29. Winslow, J.T., Insel, T.R., Trullas, R., Skolnick, P. Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex. Eur J Pharmacol 1990, 190: 11-21.
30. Stephens, D.N., Andrews, J.S. N-methyl-D-aspartate antagonists in animal models of anxiety. In: Frontiers in Excitatory Amino Acid Research. Neurology and Neurobiology. Cavalheiro, E.A., Lehmann, J., Turski, L. (Eds.). Alan R.Liss, Inc 1988, 46: 309-16.
31. Jessa, M., Nazar, M., Plaznik, A. Anxiolytic-like action of intra-hippocampally administered NMDA antagonists in rats. Pol J Pharmacol 1995, 47: 81-4.
32. Anthony, E.W., Nevins, M.E. Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 1993, 250: 317-24.
33. Guimaraes, F.S., Carobrez, A.P., De Aguiar, J.C., Graeff, F.G. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology (Berl) 1991, 103: 91-4.
34. Miserendino, M.J., Sananes, C.B., Melia, K.R., Davis, M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 1990, 345: 716-8.
35. Przegalinski, E., Tatarczynska, E., Chojnacka-Wojcik, E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 2000, 39: 1858-64.
36. Przegalinski, E., Tatarczynska, E., Deren-Wesolek, A., Chojnacka-Wojcik, E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 1996, 54: 73-7.
37. Dunn, R.W., Flanagan, D.M., Martin, L.L. et al. Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur J Pharmacol 1992, 214: 207-14.
38. B receptor partial agonist, D-cycloserine, in rats. Pharmacological analysis. Psychopharmacology (Berl) 2000, 52: 224-8.
39. Kehne, J.H., Baron, B.M., Harrison, B.L. et al. MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles. Eur J Pharmacol 1995, 284: 109-18.
40. Baron, B.M., Harrison, B.L., Kehne, J.H. et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 1997, 323: 181-92.
41. B receptors. Pol J Pharmacol 1998, 50: 349-54.
42. Sanger, D.J., Jackson, A. Effects of phencyclidine and other N-methyl-D-aspartate antagonists on the schedule -controlled behavior of rats. J Pharmacol Exp Ther 1989, 248: 1215-21.
43. Wiley, J.L., Compton, A.D., Holcomb, J.D. et al. Effects of modulation of NMDA neurotransmission on response rate and duration in a conflict procedure in rats. Neuropharmacology 1998, 37: 1527-34.
44. Koek, W., Colpaert, F.C. Use of a conflict procedure in pigeons to characterize anxiolytic drug activity: Evaluation of N-methyl-D-aspartate antagonists. Life Sci 1991, 49: L37-L42.
45. Porsolt, R.D., Bertin, A., Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229: 327-36.
46. Porsolt, R.D., Anton, G., Blavet, N., Jalfre, M. Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47: 379-91.
47. Steru, L., Chermat, R., Thierry, B., Simon, P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85: 367-70.
48. Trullas, R., Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185: 1-10.
49. Maj, J., Rogoz, Z., Skuza, G., Sowinska, H. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol J Pharmacol Pharm 1992, 44: 337-46.
50. Maj, J., Rogoz, Z., Skuza, G. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Pol J Pharmacol Pharm 1992, 44: 217-26.
51. Panconi, E., Roux, J., Altenbaumer, M., Hampe, S., Porsolt, R.D. MK-801 and enantiomers: Potential antidepressants or false positives in classical screening models? Pharmacol Biochem Behav 1993, 46: 15-20.
52. Papp, M., Moryl, E., Willner, P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996, 296: 129-36.
53. Papp, M., Moryl, E. New evidence for the antidepressant activity of MK-801, a non- competitive antagonist of NMDA receptors. Pol J Pharmacol 1993, 45: 549-53.
54. Papp, M., Moryl, E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994, 263: 1-7.
55. Chaturvedi, H.K., Bapna, J.S., Chandra, D. Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. Indian J Physiol Pharmacol 2001, 45: 199-207.
56. Ossowska, G., Klenk-Majewska, B., Szymczyk, G. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J Physiol Pharmacol 1997, 48: 127-35.
57. Redmond, A.M., Kelly, J.P., Leonard, B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997, 58: 355-9.
58. Jesberger, J.A., Richardson, J.S. Brain output dysregulation induced by olfactory bulbectomy: An approximation in the rat of major depressive disorder in humans? Int J Neurosci 1988, 38: 241-65.
59. Cairncross, K.D., Cox, B., Forster, C., Wren, A.F. Olfactory projection systems, drugs and behaviour: A review. Psychoneuroendocrinology 1979, 4: 253-72.
60. Jancsar, S.M., Leonard, B.E. Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8: 263-9.
61. Leonard, B.E., Tuite, M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 1981, 22: 251-86.
62. Lloyd, K.G., Morselli, P.L., Depoortere, H. et al. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 1983, 18: 957-66.
63. Koek, W., Colpaert, F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 1990, 252: 349-57.
64. Loscher, W., Annies, R., Honack, D. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 1993, 242: 263-74.
65. Carter, A.J. Antagonists of the NMDA receptor-channel complex and motor coordination. Life Sci 1995, 57: 917-29.
66. Toru, M., Kurumaji, A., Ishimaru, M. Excitatory amino acids: Implications for psychiatric disorders research. Life Sci 1994, 55: 1683-99.
67. Przegalinski, E., Tatarczynska, E., Derenwesolek, A., Chojnackawojcik, E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997, 36: 31-7.
68. Hesselink, M.B., Smolders, H., Deboer, A.G., Breimer, D.D., Danysz, W. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration. Behav Pharmacol 1990, 10: 85-98.
69. Maj, J., Rogoz, Z. Synergistic effect of amantadine and impramine in the forced swimming test. Pol J Pharmacol 2000, 52: 111-4.
70. Kornhuber, J., Quack, G., Danysz, W. et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995, 34: 713-21.
71. Ferszt, R., Kuhl, K.P., Bode, L. et al. Amantadine revisited: An open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry 1999, 32: 142-7.
72. Huber, T.J., Dietrich, D.E., Emrich, H.M. Possible use of amantadine in depression. Pharmacopsychiatry 1999, 32: 47-55.
73. Berman, R.M., Cappiello, A., Anand, A. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47: 351-4.
74. Lopes, T., Neubauer, P., Boje, K.M.K. Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav 1997, 58: 1059-64.
75. Vamvakides, A. D-cycloserine is active in the adult mouse and inactive in the aged mouse, in the forced swim test. Ann Pharm Fr 1998, 56: 209-12.
76. Papp, M., Moryl, E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 1996, 316: 145-51.
77. Maj, J., Rogoz, Z., Skuza, G., Kolodziejczyk, K. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7-dichloro-kynurenic acid, glycine site antagonists. Pol J Pharmacol 1994, 46: 115-24.
78. Parsons, C.G., Danysz, W., Hesselink, M. et al. Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments. Amino Acids 1998, 14: 207-16.
79. Skolnick, P., Miller, R., Young, A., Boje, K., Trullas, R. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology (Berl) 1992, 107: 489-96.
80. Layer, R.T., Popik, P., Olds, T., Skolnick, P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995, 52: 621-7.
81. Kroczka, B., Branski, P., Palucha, A., Pilc, A., Nowak, G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 2001, 55: 297-300.
82. Kroczka, B., Zieba, A., Dudek, D., Pilc, A., Nowak, G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J Pharmacol 2000, 52: 403-6.
83. Decollogne, S., Tomas, A., Lecerf, C., Adamowicz, E., Seman, M. NMDA receptor complex blockade by oral administration of magnesium: Comparison with MK-801. Pharmacol Biochem Behav 1997, 58: 261-8.
84. Turski, L., Jacobsen, P., Honore, T., Stephens, D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther 1992, 260: 742-7.
85. Karcz-Kubicha, M., Liljequist, S. Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur J Pharmacol 1995, 279: 171-7.
86. Czlonkowska, A., Siemiatkowski, M., Plaznik, A. Some behavioral effects of AMPA/kainate receptor agonist and antagonists. J Physiol Pharmacol 1997, 48: 479-88.
87. Matheus, M.G., Guimaraes, F.S. Antagonism of non-NMDA receptors in the dorsal periaqueductal grey induces anxiolytic effect in the elevated plus maze. Psychopharmacology (Berl) 1997, 132: 14-8.
88. Kotlinska, J., Liljequist, S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav 1998, 60: 119-24.
89. Li, X., Tizzano, J.P., Griffey, K., Clay, M., Lindstrom, T., Skolnick, P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40: 1028-33.
90. Nakamura, K., Kurasawa, M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol 2001, 420: 33-43.
91. Gasparini, F., Lingenhohl, K., Stoehr, N. et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38: 1493-503.
92. Varney, M.A., Cosford, N.D.P., Jachec, C. et al. SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 1999, 290: 170-81.
93. Spooren, W.P., Vassout, A., Neijt, H.C. et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000, 295: 1267-75.
94. Tatarczynska, E., Klodzinska, A., Chojnacka-Wojcik, E. et al. Potential anxiolytic- and antidepressant effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132: 1423-30.
95. Klodzinska, A., Tatarczynska, E., Chojnacka-Wojcik, E., Pilc, A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. Pol J Pharmacol 2000, 52: 463-6.
96. Tatarczynska, E., Klodzinska, A., Kroczka, B., ChojnackaWojcik, E., Pilc, A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmcology 2001, 158: 94-9.
97. Spooren, W.P., Gasparini, F., Salt, T.E., Kuhn, R. Novel allosteric antagonists shed light on mGlu5 receptors and CNS disorders. Trends Pharmacol Sci 2001, 22: 331-7.
98. Schulz, B., Fendt, M., Gasparini, F., Lingenhohl, K., Kuhn, R., Koch, M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001, 41: 1-7.
99. Chojnacka Wojcik, E., Tatarczynska, E., Pilc, A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 1997, 319: 153-6.
100. Aron, C., Simon, P., Larousse, C., Boissier, J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1991, 10: 459-69.
101. Wieronska, J., Kroczka, B., Branski, P., Pilc, A. Antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002, in press.
102. Pellicciari, R., Luneia, R., Costantino, G. et al. 1-Aminoindan-1,5-dicarboxylic acid: A novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J Med Chem 1995, 38: 3717-9.
103. Bond, A., Monn, J.A., Lodge, D. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. Neuroreport 1997, 8: 1463-6.
104. Monn, J.A., Valli, M.J., Massey, S.M. et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999, 42: 1027-40.
105. Helton, D.R., Tizzano, J.P., Monn, J.A., Schoepp, D.D., Kallman, M.J. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998, 284: 651-60.
106. Monn, J.A., Valli, M.J., Massey, S.M. et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997, 40: 528-37.
107. Klodzinska, A., Chojnacka-Wojcik, E., Palucha, A., Branski, P., Popik, P., Pilc, A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999, 38: 1831-9.
108. Benvenga, M.J., Overshiner, C.D., Monn, J.A., Leander, J.D. Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons. Drug Dev Res 1999, 47: 37-44.
109. Chojnacka-Wojcik, E., Tatarczynska, E., Pilc, A. Anxiolytic-like effects of metabotropic glutamate antagonist (RS)-α-methylserine-O-phosphate in rats. Pol J Pharmacol 1996, 48: 507-9.
110. Pilc, A., Chojnacka-Wojcik, E., Tatarczynska, E., Borycz, J., Kroczka, B. Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids 2000, 19: 81-6.
111. Helton, D.R., Tizzano, J.P., Monn, J.A., Schoepp, D.D., Kallman, M.J. LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 1997, 36: 1511-6.
112. Popik, P., Kozela, E., Pilc, A. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Brit J Pharmacol 2000, 130: 1425-31.
113. Schoepp, D.D., Jane, D.E., Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38: 1431-76.
114. Shigemoto, R., Kinoshita, A., Wada, E. et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997, 17: 7503-22.
115. Okamoto, N., Hori, S., Akazawa, C. et al. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 1994, 269: 1231-6.
116. Corti, C., Restituito, S., Rimland, J.M. et al. Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8. Eur J Neurosci 1998, 10: 3629-41.
117. Nowak, G., Trullas, R., Layer, R.T., Skolnick, P., Paul, I.A. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993, 265: 1380-6.
118. Nowak, G., Li, Y., Paul, I.A. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur J Pharmacol 1996, 295: 75-85.
119. Nowak, G., Legutko, B., Skolnick, P., Popik, P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol 1998, 342: 367-70.
120. Paul, I.A., Layer, R.T., Skolnick, P., Nowak, G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 1993, 247: 305-11.
121. Paul, I.A., Nowak, G., Layer, R.T., Popik, P., Skolnick, P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994, 269: 95-102.
122. Stewart, C., Jeffery, K., Reid, I. LTP-like synaptic efficacy changes following electroconvulsive stimulation. Neuroreport 1994, 5: 1041-4.
123. Nonaka, S., Hough, C.J., Chuang, D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998, 95: 2642-7.
124. Popik, P., Wrobel, M., Nowak, G. Chronic treatment with antidepressants affects glycine/NMDA receptor function: Behavioral evidence. Neuropharmacology 2000, 39: 2278-87.
125. Vaidya, V.A., Duman, R.S. Depression - emerging insights from neurobiology. Br Med Bull 2001, 57: 61-79.
126. Pilc, A. The influence of prolonged antidepressant treatment on the changes in cAMP accumulation induced by excitatory amino acids in cerebral cortical slices of rat. Biol Psychiatr 1991, 29: 347S-8S.
127. Pilc, A., Legutko, B. Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain. Pol J Pharmacol 1995, 47: 359-61.
128. Pilc, A., Legutko, B. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Neuroreport 1995, 7: 85-8.
129. Pilc, A., Legutko, B., Czyrak, A. The enhancement and the inhibition of noradrenaline-induced cyclic AMP accumulation in rat brain by stimulation of metabotropic glutamate receptors. Prog Neuro-Psych Biol Psych 1996, 20: 673-90.
130. Palucha, A, Branski, P., Kroczka, B., Pilc, A. Possible involvement of mGluR1 together with group II and III mGluRs in ibotenate-stimulated cAMP formation in the rat brain cortical slices. Pol J Pharmacol 2000, 52: 353-8.
131. Pilc, A., Branski, P., Palucha, A., Tokarski, K., Bijak, M. Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA 1 region. Eur J Pharmacol 1998, 349: 83-7.
132. Zahorodna, A., Bijak, M. An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur J Pharmacol 1999, 386: 173-9.
133. Bajkowska, M., Branski, P., Smialowska, M., Pilc, A. Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuR1a immunoreactivity expression in the rat hippocampus. Pol J Pharmacol 1999, 51: 539-41.
134. Smialowska, M., Szewczyk, B., Branski, P. et al. Effect of chronic imipramine or electrocomvulsove shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 2002, submitted.
135. Glaum, S.R., Miller, R.J. Acute regulation of synaptic transmission by metabotropic glutamate receptors. In: The Metabotropic Glutamate Receptors. Conn, P.J., Patel, J. (Eds.). Human Press: Totowa 1994, 147-72.
136. Fitzjohn, S.M., Irving, A.J., Palmer, M.J., Harvey, J., Lodge, D., Collingridge, G.L. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci Lett 1996, 203: 211-3.
137. Ugolini, A., Corsi, M., Bordi, F. Potentiation of NMDA and AMPA responses by the specific mGluR(5) agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999, 38: 1569-76.